A plain-English look at Pfizer's revenue, profit, dividend, and market value based on the company's latest public filings and trading data.
Pfizer has been making medicine in one form or another since 1849, back when the company started as a small chemical business in New York. Today Pfizer is one of the largest pharmaceutical companies on Earth, and its latest numbers tell a story of a mature, still-profitable giant that has shrunk from its recent peak.
What Pfizer Actually Sells
Pfizer's business has narrowed over the decades. It once sold a wide range of healthcare products and chemicals, but prescription drugs and vaccines now make up the bulk of its sales. Its best-known products include the pneumococcal vaccine Prevnar 13 and the cardiology drugs Vyndaqel and Eliquis.
A Global Footprint
Pfizer isn't just an American story. International sales account for 40% of total revenue, with emerging markets contributing a meaningful share of that international business.
Sizing Up the Revenue
In fiscal year 2025, Pfizer generated $62.6 billion in revenue. That's a scale few companies in any industry reach, and it places Pfizer firmly among the world's largest pharmaceutical firms, consistent with its own description of roughly $60 billion in annual sales.
A Notable Decline
That revenue figure represents a 23% drop from fiscal year 2021 to fiscal year 2025. For a company of this size, that's a significant contraction, and it reflects a business that has cooled off considerably from a recent high point.
Profit Still Flows
Despite the shrinking top line, Pfizer remains solidly profitable. The company reported net income of $7.8 billion in fiscal year 2025, meaning it turned a meaningful profit even as overall sales declined.
Margins in Context
Pfizer's gross margin stands at 74.3%, which shows how much revenue is left after the direct costs of making its drugs. Its net margin of 12.5% reflects what's left after all expenses, including research, marketing, and administration.
Balance Sheet Heft
Pfizer's total assets add up to $208.2 billion, a figure that speaks to the scale of its factories, cash, patents, and other holdings built up over more than a century and a half in business.
How the Market Values It
On the stock market, Pfizer carries a market capitalization of $148.4 billion. Its shares recently traded at $24.25, a price that sits 15% below the stock's 52-week high.
The Price-to-Earnings Picture
Pfizer trades at a price-to-earnings ratio of 17.8. That ratio compares the company's stock price to its profits, giving a sense of how the market is currently pricing Pfizer's earnings relative to its share price.
The Dividend Angle
One notable feature of Pfizer's stock is its dividend, which yields about 7.09% annually at current prices. That's a substantial payout relative to the share price, and it's a detail income-focused shareholders often watch closely.
Scale of Operations
Running a business this size takes people. Pfizer employs approximately 75,000 workers, and the company has been publicly traded since its 1951 initial public offering, listed on the New York Stock Exchange under the ticker PFE.
Putting the Numbers Together
Taken as a whole, the picture is a company still generating tens of billions in revenue and billions in profit, even as its sales have contracted meaningfully in recent years. Strong margins and a large asset base suggest underlying operational strength, while the falling revenue and depressed share price point to real headwinds.
This article is factual reporting drawn from public filings and market data, not investment advice.
